Qube Research & Technologies (QRT)
ABOS icon

Qube Research & Technologies (QRT)’s Acumen Pharmaceuticals ABOS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Sell
38,614
-81,774
-68% -$202K ﹤0.01% 3010
2026
Q1 		$284K Buy
120,388
+72,403
+151% +$185K ﹤0.01% 2878
2025
Q4 		$101K Buy
47,985
+15,104
+46% +$30K ﹤0.01% 3189
2025
Q3 		$56.2K Sell
32,881
-24,678
-43% -$34.1K ﹤0.01% 3167
2025
Q2 		$66.8K Buy
57,559
+35,424
+160% +$38.1K ﹤0.01% 3099
2025
Q1 		$24.3K Sell
22,135
-46,186
-68% -$66K ﹤0.01% 3204
2024
Q4 		$118K Sell
68,321
-14,381
-17% -$34.6K ﹤0.01% 2955
2024
Q3 		$205K Buy
82,702
+6,833
+9% +$18.5K ﹤0.01% 2577
2024
Q2 		$184K Sell
75,869
-91,719
-55% -$292K ﹤0.01% 2448
2024
Q1 		$679K Buy
167,588
+78,962
+89% +$298K ﹤0.01% 2370
2023
Q4 		$340K Buy
88,626
+62,513
+239% +$186K ﹤0.01% 2515
2023
Q3 		$108K Buy
+26,113
New +$161K ﹤0.01% 2634
2023
Q2 		– Sell
-44,385
Closed -$180K – 2336
2023
Q1 		$180K Sell
44,385
-8,978
-17% -$46.9K ﹤0.01% 1964
2022
Q4 		$288K Buy
53,363
+36,650
+219% +$246K ﹤0.01% 1666
2022
Q3 		$168K Sell
16,713
-5,546
-25% -$31.8K ﹤0.01% 1820
2022
Q2 		$105K Buy
+22,259
New +$83.6K ﹤0.01% 1934

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ABOS Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Acumen Pharmaceuticals (ABOS) stake by 68% in Q2 2026, selling an estimated $202K and leaving 38,614 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #3010.

Qube Research & Technologies (QRT) first reported a position in ABOS in Q2 2022 and has held it in 16 quarters since. The position peaked at $679K in Q1 2024. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Qube Research & Technologies (QRT) held 38,614 shares of Acumen Pharmaceuticals worth $103K as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 81,774 Acumen Pharmaceuticals shares in Q2 2026, an estimated $202K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #3010 holding.
  • Qube Research & Technologies (QRT) first reported a position in Acumen Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • Qube Research & Technologies (QRT)'s Acumen Pharmaceuticals position peaked at $679K in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.